A vs. AZN: Agilent vs. AstraZeneca Stock Comparison

November 11, 2026

How do Agilent (A) and AstraZeneca (AZN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and AstraZeneca (AZN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while AZN is classified in Pharmaceuticals.

Agilent (A) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Agilent (A) and AstraZeneca (AZN)
Profile Item	A	AZN
Name	AgileThought, Inc. Class A Common Stock	AstraZeneca PLC American Depositary Shares
Country/Region	United States	United Kingdom
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Pharmaceuticals
GICS Sub-Industry	Life Sciences Tools & Services	Pharmaceuticals
Market Capitalization	49.28 billion USD	289.14 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	November 18, 1999	May 12, 1993
Security Type	Common Stock	ADR

Price Performance

Cumulative Growth

AZN

GSPC

Agilent (A) vs. AstraZeneca (AZN), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Agilent (A) and AstraZeneca (AZN). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Agilent (A) and AstraZeneca (AZN). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and AstraZeneca (AZN)
Metric	A	AZN
Total Return (1Y)	22.92%	12.64%
Total Return (3Y, Annualized)	19.33%	15.75%
Total Return (5Y, Annualized)	3.03%	10.63%

Risk Profile

Drawdown History

AZN

GSPC

Agilent (A) vs. AstraZeneca (AZN), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Agilent (A) and AstraZeneca (AZN). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and AstraZeneca (AZN)
Metric	A	AZN
Volatility (1Y, Annualized)	33.10%	28.21%
Beta (5Y)	1.22	0.22
Max Drawdown (5Y)	-38.09%	-27.87%
Avg. Volume (3M)	2.25M	3.14M

Risk-Adjusted Performance

Risk-Return Positioning

A and AZN are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and AstraZeneca (AZN)
Metric	A	AZN
Sharpe Ratio (1Y)	0.56	0.30
Sortino Ratio (1Y)	0.96	0.44

Profitability

ROE (TTM)

Both Agilent (A) at 20.97% and AstraZeneca (AZN) at 22.57% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max: 109.18%
A: 20.97%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.57%

Max: 109.18%
AZN: 22.57%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Agilent (A) vs. AstraZeneca (AZN): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Agilent (A) at 19.53% keeps the most of each sales dollar — above its industry’s net margin range — and AstraZeneca (AZN) at 17.68% also retains a top-quartile share.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A: 19.53%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.68%

Max: 18.05%
AZN: 17.68%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Agilent (A) vs. AstraZeneca (AZN): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and AstraZeneca (AZN) at 29.57% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max: 83.12%
A: 25.56%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.57%

Max: 83.12%
AZN: 29.57%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Agilent (A) vs. AstraZeneca (AZN): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and AstraZeneca (AZN)
Metric	A	AZN
ROE (TTM)	20.97%	22.57%
ROA (TTM)	8.63%	8.59%
Net Margin (TTM)	19.53%	17.68%
Operating Margin (TTM)	25.56%	29.57%
Gross Margin (TTM)	53.65%	81.78%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and AstraZeneca (AZN) at 8.63% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Agilent (A) vs. AstraZeneca (AZN): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Agilent (A) at 3.16% and AstraZeneca (AZN) at 45.33% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Agilent (A) vs. AstraZeneca (AZN): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and AstraZeneca (AZN)
Metric	A	AZN
Revenue Growth (YoY)	6.73%	8.63%
Revenue Growth (3Y CAGR)	0.48%	9.82%
EPS Growth (YoY)	3.16%	45.33%
EPS Growth (3Y CAGR)	3.02%	45.80%

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and AstraZeneca (AZN) at 1.01 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
A: 2.05
Min: 0.10

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AZN: 1.01
Min: 0.10

Agilent (A) vs. AstraZeneca (AZN): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Agilent (A) at 0.56 carries an industry-typical debt-to-equity mix, while AstraZeneca (AZN) at 0.66 uses more debt funding than most peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max: 1.42
Q3: 0.65
A: 0.56
Median: 0.15
Q1: 0.02
Min: 0.00

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.66

Max: 1.42
AZN: 0.66
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Agilent (A) vs. AstraZeneca (AZN): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and AstraZeneca (AZN)
Metric	A	AZN
Current Ratio (MRQ)	2.05	1.01
Debt / Equity (MRQ)	0.56	0.66
Net Debt / EBITDA	1.15	1.23

Dividends

Dividend Yield (TTM)

Both Agilent (A) at 0.59% and AstraZeneca (AZN) at 1.73% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A: 0.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73%

AZN: 1.73%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. AstraZeneca (AZN): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Agilent (A) at 19.98% and AstraZeneca (AZN) at 45.38% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A: 19.98%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.38%

AZN: 45.38%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. AstraZeneca (AZN): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and AstraZeneca (AZN)
Metric	A	AZN
Dividend Yield (TTM)	0.59%	1.73%
Dividend Payout Ratio (TTM)	19.98%	45.38%

Valuation

P/E Ratio (TTM)

Both Agilent (A) at 34.47 and AstraZeneca (AZN) at 26.37 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max: 85.34
Q3: 43.46
A: 34.47
Median: 26.69
Q1: 13.30
Min: 0.07

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.37

Max: 85.34
Q3: 43.46
Median: 26.69
AZN: 26.37
Q1: 13.30
Min: 0.07

Agilent (A) vs. AstraZeneca (AZN): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and AstraZeneca (AZN) at 4.63 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max: 58.18
Q3: 25.77
Median: 7.30
A: 6.68
Q1: 3.01
Min: 0.01

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.63

Max: 58.18
Q3: 25.77
Median: 7.30
AZN: 4.63
Q1: 3.01
Min: 0.01

Agilent (A) vs. AstraZeneca (AZN): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AstraZeneca (AZN) at 5.59 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 13.53
A: 6.69
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.59

Max: 13.53
Q3: 6.54
AZN: 5.59
Median: 3.25
Q1: 1.69
Min: -5.59

Agilent (A) vs. AstraZeneca (AZN): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and AstraZeneca (AZN)
Metric	A	AZN
P/E Ratio (TTM)	34.47	26.37
P/S Ratio (TTM)	6.68	4.63
P/B Ratio (MRQ)	6.69	5.59
Free Cash Flow Yield (TTM)	2.15%	1.95%